VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

ImeVRTXON

PoredakNo.3700

Tržišna kapitalizacija$0.00

Potpuno razrijeđena tržišna kapitalizacija$0.00

Tržišni udio%

Obujam trgovanja / tržišna kapitalizacija (24-satni)55,312,211.40%

Količina u optjecaju1.30452605

Maksimalna količina0

Ukupna količina1.30452605

Stopa optjecaja%

Datum izdavanja--

Cijena po kojoj je imovina prvi put izdana--

Najviša vrijednost svih vremena466.35223147502205,2026-03-26

Najniža cijena414.92035330237934,2026-05-05

Javni blockchainETH

UvodVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Društvene mreže

• Službena web-stranica
• Blokiraj pretraživač

etfindex:mc_etfindex_sourceOdricanje od odgovornosti: Podatke pruža cmc i ne smiju se smatrati investicijskim savjetom.